 |
|
NEJM study finds drug-eluting stents more effective than bare-metal stents in heart attack patients
May 27, 2009Landmark Horizons-AMI study led by NewYork-Presbyterian Hospital and Columbia University Medical Center in collaboration with the Cardiovascular Research Foundation
NEW YORK -- NewYork-Presbyterian Hospital and Columbia University Medical Center, together with the Cardiovascular Research Foundation (CRF), announced that its landmark study comparing the safety and efficacy of drug-eluting stents and bare-metal stents was published in the May 7 New England Journal of Medicine. The study, HORIZONS-AMI (Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction), showed that in heart attack patients undergoing angioplasty, the use of paclitaxel-eluting stents reduces rates of target lesion revascularization (TLR) and binary angiographic restenosis when compared to the use of bare-metal stents after one year.
Additionally, the primary safety measure of major adverse cardiovascular events (MACE), including death, reinfarction, stent thrombosis and stroke established the non-inferiority of drug-eluting stents with respect to safety through one year.
The study was led by Dr. Gregg W. Stone, director of cardiovascular research and education in the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center; and professor of medicine at Columbia University College of Physicians and Surgeons. The research was sponsored and managed by the Cardiovascular Research Foundation with research grant support from Boston Scientific Corporation and The Medicines Company.
In the trial, the use of paclitaxel-eluting stents resulted in a significant reduction of ischemia-driven target-lesion revascularization (TLR) at 12 months (4.5% vs. 7.5%). TLR, which was the primary efficacy endpoint of the trial, refers to the rate at which a particular lesion re-narrows following stent implantation severely enough to require either a repeat angioplasty or bypass surgery operation.
The use of paclitaxel-eluting stents also resulted in a significant reduction in binary restenosis after 13 months, which is the rate at which the artery re-narrows at least 50 percent following implantation of the stent, and was the secondary efficacy endpoint of the trial. The paclitaxel-eluting stent had a rate of 10.0 percent and the bare-metal stent had a rate of 22.9 percent.
"Outcomes from prior registry and randomized trials of drug-eluting stents compared with bare-metal stents in heart attack patients have been conflicting. These results now provide definitive evidence that paclitaxel-eluting stents are superior in efficacy to bare-metal stents and have a comparable safety profile at one year," says Dr. Stone. "The findings from the HORIZONS-AMI trial will have a major impact on how decisions are made regarding drug-eluting and bare-metal stents in the highest-risk patients, those in the early hours of a heart attack. This study removes much of the uncertainty and concern about the efficacy and safety of drug-eluting stents in this clinical setting. Moreover, all of the patients in this trial will be followed long-term to ensure that these favorable results are maintained."
The HORIZONS-AMI trial, a prospective, open-label, multicenter, controlled study, enrolled 3,602 heart attack patients at 123 centers in 11 countries, 3,006 of whom were randomized to paclitaxel-eluting stents versus otherwise identical bare-metal stents.
New York- Presbyterian Hospital/Columbia University Medical Center
The study was led by Dr. Gregg W. Stone, director of cardiovascular research and education in the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center; and professor of medicine at Columbia University College of Physicians and Surgeons. The research was sponsored and managed by the Cardiovascular Research Foundation with research grant support from Boston Scientific Corporation and The Medicines Company.
In the trial, the use of paclitaxel-eluting stents resulted in a significant reduction of ischemia-driven target-lesion revascularization (TLR) at 12 months (4.5% vs. 7.5%). TLR, which was the primary efficacy endpoint of the trial, refers to the rate at which a particular lesion re-narrows following stent implantation severely enough to require either a repeat angioplasty or bypass surgery operation.
The use of paclitaxel-eluting stents also resulted in a significant reduction in binary restenosis after 13 months, which is the rate at which the artery re-narrows at least 50 percent following implantation of the stent, and was the secondary efficacy endpoint of the trial. The paclitaxel-eluting stent had a rate of 10.0 percent and the bare-metal stent had a rate of 22.9 percent.
"Outcomes from prior registry and randomized trials of drug-eluting stents compared with bare-metal stents in heart attack patients have been conflicting. These results now provide definitive evidence that paclitaxel-eluting stents are superior in efficacy to bare-metal stents and have a comparable safety profile at one year," says Dr. Stone. "The findings from the HORIZONS-AMI trial will have a major impact on how decisions are made regarding drug-eluting and bare-metal stents in the highest-risk patients, those in the early hours of a heart attack. This study removes much of the uncertainty and concern about the efficacy and safety of drug-eluting stents in this clinical setting. Moreover, all of the patients in this trial will be followed long-term to ensure that these favorable results are maintained."
The HORIZONS-AMI trial, a prospective, open-label, multicenter, controlled study, enrolled 3,602 heart attack patients at 123 centers in 11 countries, 3,006 of whom were randomized to paclitaxel-eluting stents versus otherwise identical bare-metal stents.
New York- Presbyterian Hospital/Columbia University Medical Center
Stents Current Events and Stents News RSSYour Own Stem Cells Can Treat Heart Disease
The largest national stem cell study for heart disease showed the first evidence that transplanting a potent form of adult stem cells into the heart muscle of subjects with severe angina results in less pain and an improved ability to walk. The transplant subjects also experienced fewer deaths than those who didn't receive stem cells.
Vitamin B niacin offers no extra benefit to statin therapy in seniors already diagnosed with CAD
The routine prescription of extended-release niacin, a B vitamin (1,500 milligrams daily), in combination with traditional cholesterol-lowering therapy offers no extra benefit in correcting arterial narrowing and diminishing plaque buildup in seniors who already have coronary artery disease, a new vascular imaging study from Johns Hopkins experts shows.
Higher carotid arterial stenting rates associated with poorer clinical outcomes
Among eligible Medicare beneficiaries, increased use of carotid arterial stenting (CAS) procedures to treat carotid stenosis-the narrowing of the carotid artery-is associated with higher rates of mortality and adverse clinical outcomes, including heart attack and stroke, according to researchers from the University of Pennsylvania School of Medicine.
Drug-eluting stents better than bare-metal stents for heart attack patients
Late-breaking data from the landmark HORIZONS-AMI clinical trial, presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, demonstrated that after two years, in heart attack patients, the use of a drug-eluting stent (paclitaxel) was safer and more effective than a bare-metal stent; and that the administration of the anticoagulant medication bivalirudin enhanced safety and efficacy compared to the use of heparin + GPIIb/IIIa inhibitors.
SPIRIT IV trial shows everolimus stent sets new standard for event-free survival
Late-breaking data from SPIRIT IV, a large-scale multi-center study of nearly 4,000 patients in the U.S., shows that an everolimus-eluting stent demonstrated enhanced safety and efficacy in the treatment of de novo native coronary artery lesions when compared to a paclitaxel-eluting stent, and showed that "low late loss" may be achieved with drug-eluting stents without sacrificing safety.
Drug-eluting stents safe, effective for treatment of chronic total occlusions
A multicenter study in Asia found drug-eluting stents effective with a low rate of acute complications in patients with chronic total occlusions (CTOs) undergoing PCI. Results of the study will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).
Researchers find drug-eluting stents safe, effective for PCI in diabetics
Results of a multicenter study in Asia, demonstrating that drug-eluting stents are effective with a low rate of complications in diabetic patients, will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).
New type of sirolimus-eluting stent demonstrates superior results
A new type of sirolimus-eluting stent (SES) successfully showed significantly greater neointimal suppression than the paclitaxel-eluting stent (PES) with greater vessel wall integrity surrounding the stent, confirming the finding of superiority of the SES over the PES stent for the trial's primary endpoint of in-stent late loss.
Laser processes promise better artificial joints, arterial stents
Researchers are developing technologies that use lasers to create arterial stents and longer-lasting medical implants that could be manufactured 10 times faster and also less expensively than is now possible.
Stent for life initiative
Primary angioplasty (with stent implantation) is the most effective therapy for acute myocardial infarction (AMI), but it is not available to many patients, even though most European countries have sufficient resources (ie, catheterisation laboratories) for its wider use.
More Stents Current Events and Stents News Articles
 |
Handbook of Coronary Stents by Patrick W. Serruys (Editor), Benno J. Rensing (Editor) Erasmus Univ., Rotterdam, The Netherlands. Handbook provides details of all the specifications of the currently available stents and illustrates each chapter with case studies and photographs of the stents themselves. Previous edition: c2000. |
 |
Acmi Corporation Stent Hc Db Pigtail 7.0frx26cm by ACMI Corporation ACMI CORPORATION STENT HC DB PIGTAIL 7.0FRX26CM : ACMI CORPORATION STENT HC DB PIGTAIL 7.0FRX26CM |
 |
Drug-eluting Stents: Are they Safe? Drug-eluting stents are metal mesh tubes coated with medication that keep arteries from re-blocking after angioplasty. These devices have been the solution for millions of people around the world. However, recent studies have raised concerns about associated risks. Join Dr. Yeung and colleagues as they discuss the safety of these popular devices This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
|
KR3W The Dixon Stent Jacket,Jackets for Men, Medium,Teal by KR3W KR3W The Dixon Stent Jacket,Jackets for Men: Model is wearing a size MEDIUM The Dixon Stent Jacket has a 100% cotton shell and 100% polyester lining and filling and features a supersoft cotton knit with a lumberjack knit pattern a button-down front and two buttoned chest pockets. By KR3W | |
 |
STENT 'S Beer and Ale Cascading Pub Wall Clock by ZuWEE 9" Black Plastic Wall Clock. Brand new in box. Precision quartz movement operates on one AA battery (not included). This is not a lighted clock. |
 |
Stents and Sensibility Starring: Dr. James Ferguson Directed By: John Siceloff Also With: John Siceloff (Producer), David Brancaccio (Writer) |
![Ooh La La [4 track Aussie maxi single]](http://ecx.images-amazon.com/images/I/41lSQrycZtL._SL160_.jpg) |
Ooh La La [4 track Aussie maxi single] Goldfrapp (Performer), Mark "Spike" Stent (Performer), Benny Benassi (Performer), Phones (Performer), Jochen Schmalbach (Performer), Tiefschwarz (Performer), Charlie Jones (Performer), Adrian Utley (Performer), Nick Batt (Performer) Tracklisting: 1 Ooh La La (Radio Version) (2:56) Mixed By - Mark "Spike" Stent* 2 Ooh La La (Benny Benassi Remix - Extended) (6:50) Remix - Alle Benassi , Benny Benassi 3 Ooh La La (Phones Re-Edit) (6:29) Remix - Phones 4 Ooh La La (Tiefschwarz Dub) (6:36) Remix - Jochen Schmalbach , Tiefschwarz |
 |
When The Blues Get The Cup Harvey Andrews with Guest Narrator Malcolm Stent (Primary Contributor) |
 |
STENT Street Sign ~ Personalized Family Lastname Sign ~ Gameroom, Basement, Garage Sign Novelty** METAL ALUMINUM by The Lizton Sign Shop STENT Street Sign, A BRAND NEW SIGN!! Made of aluminum and high quality vinyl lettering and graphics this sign is 4 x 18 inches. Made to last for years outdoors the sign is nice enough to display indoors. Comes with two holes pre-punched for easy installation, corners are rounded. |
 |
Phage And the Origins of Molecular Biology, The Centennial Edition by John Cairns (Editor), Gunther S. Stent (Editor), James D. Watson (Editor) This hugely influential book, published in 1966 as a 60th birthday tribute to Max Delbrück, is now republished as The Centennial Edition. On first publication, the book was hailed as "[introducing] into the literature of science, for the first time, a self conscious historical element in which the participants in scientific discovery engage in writing their own chronicle. As such, it is an important document in the history of biology... "(Journal of History of Biology). And in another review it was described as "required reading for every student of experimental biology...[who] will sense the smell and rattle of the laboratory" (Bioscience). The book was a formative influence on many of today s leading scientists. Related Titles from the... |
| © 2009 BrightSurf.com |